文献速递眼底病与葡萄膜炎

扩展视野OCT血管成像生物标志物预测非增殖性糖尿病视网膜病变临床显著结局

Expanded Field OCT Angiography Biomarkers for Predicting Clinically Significant Outcomes in Non-Proliferative Diabetic Retinopathy.
PubMed 文献 · Am J Ophthalmol · 2024-10-28

回顾性病例对照研究纳入57例参与者共88只非增殖性糖尿病视网膜病变眼,评估基线及随访中视网膜内微血管异常(IRMA)稳定性和基线缺血指数对临床显著结局的预测价值。随访25.1±10.8个月后17眼(19.3%)出现显著临床结局,调整年龄、糖尿病病程和既往抗VEGF治疗后,非稳定IRMA(HR 3.88)和较高基线缺血指数(HR 1.05)与结局显著相关。作者认为扩展视野SS-OCTA可能为糖尿病视网膜病变分期和预测高危患者提供额外预后价值。

要点

  • 随访期间非稳定IRMA与临床显著结局相关(HR 3.88,95%CI 1.56-9.64,p=.004)。
  • 较高基线缺血指数与临床显著结局相关(HR 1.05,95%CI 1.02-1.09,p=.004)。
  • 扩展视野SS-OCTA可能为DR分期和高危患者预测提供额外预后价值。

核心结论

  • 随访中IRMA不稳定且基线缺血更重的NPDR眼发生临床显著结局的风险更高。
  • 作者认为扩展视野SS-OCTA可能为临床DR分期和预测高危患者提供额外预后价值。

研究设计与样本

  • 回顾性临床病例对照研究,单中心。
  • 纳入57例参与者的88只NPDR眼,中位年龄64.0岁,平均糖尿病病程15.8年,至少连续2次SS-OCTA扫描且随访至少6个月。
  • 在12×12-mm血管成像上评估基线IRMA存在及随访期间IRMA稳定性,在FIJI和ARI Network上计算基线非灌注缺血指数(ISI)及其他SS-OCTA指标。
  • 采用混合效应Cox回归模型探索结局。

主要发现

  • 临床随访25.1±10.8个月后,17眼(19.3%)出现显著临床结局。
  • 7眼(8.0%)发生显著DR进展,4眼(4.5%)发生新发中心受累糖尿病黄斑水肿(CI-DME)。
  • 15眼(17.0%)启动抗VEGF注射治疗,2眼(2.3%)启动全视网膜光凝(PRP)。
  • 调整年龄、糖尿病病程和既往抗VEGF治疗后,随访期间非稳定IRMA与显著临床结局相关(HR 3.88,95%CI 1.56-9.64,p=.004)。
  • 调整相同因素后,较高基线缺血指数与显著临床结局相关(HR 1.05,95%CI 1.02-1.09,p=.004)。

关键数值与推荐

  • 显著临床结局定义为末次临床访视时发生以下一项或多项:显著DR进展(2步DR进展或进展为增殖性DR(PDR));新发中心受累糖尿病黄斑水肿(CI-DME);随访期间启动PRP或抗VEGF注射治疗。

临床怎么用

  • 原文未据此给出推荐,作者认为扩展视野SS-OCTA可能为临床DR分期和预测高危患者提供额外预后价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the utility of extended field swept-source Optical Coherence Tomography Angiography (SS-OCTA) imaging biomarkers in predicting the occurrence of clinically significant outcomes in eyes with Non-Proliferative Diabetic Retinopathy (NPDR). DESIGN: Retrospective clinical case-control study. METHODS: Single-center clinical study. Eighty-eight eyes with NPDR from 57 participants (median age: 64.0 years; mean duration of diabetes: 15.8 years) with at least 2 consecutive SS-OCTA scans over a follow-up period of at least 6 months were included. The presence of intraretinal microvascular abnormalities (IRMAs) at baseline and the stability of IRMAs during follow-up period on 12 × 12-mm angiograms were evaluated. Baseline nonperfusion ischemia index (ISI) and other SS-OCTA metrics were calculated on FIJI and ARI Network. Significant clinical outcomes were defined as occurrence of one or more of the following events at the last available clinical visit:1. significant DR progression (2-step DR progression or progression to proliferative DR (PDR)); 2) development of new center-involving diabetic macular edema (CI-DME); and 3) initiation of treatment with PRP or anti-VEGF injections during the follow-up period. Mixed-effects Cox regression models was used to explore these outcomes. RESULTS: Following a clinical follow-up period lasting 25.1 ± 10.8 months, we observed significant clinical outcomes in 17 eyes (19.3%). Among these, 7 eyes (8.0%) experienced significant progression and 4 eyes (4.5%) developed CI-DME. Anti-VEGF injections were initiated in 15 eyes (17.0%), while PRP was initiated in 2 eyes (2.3%). Upon adjusting for age, the duration of DM, and prior Anti-VEGF treatments, our analysis revealed that non-stable IRMAs during the follow-up periods and a higher ischemia index at baseline were significantly associated with the occurrence of significant clinical outcomes with HRs of 3.88 (95% CI: 1.56-9.64; p = .004) and 1.05 (95% CI: 1.02-1.09; p = .004), respectively. CONCLUSIONS: In conclusion, NPDR eyes with non-stable IRMAs over time and more ischemia at baseline are in higher risk of developing significant clinical outcomes. Our findings suggest that expanded field SS-OCTA may offer additional prognostic benefits for clinical DR staging and predicting high-risk patients.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ding X, Romano F, Garg I, et al. Expanded Field OCT Angiography Biomarkers for Predicting Clinically Significant Outcomes in Non-Proliferative Diabetic Retinopathy. Am J Ophthalmol. 2024. PMID: 39490720. doi:10.1016/j.ajo.2024.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。